Full-Time

Life Sciences Growth Director

Posted on 9/11/2026

Synapticure

Synapticure

51-200 employees

24/7 telehealth neurology for neurodegenerative care

Compensation Overview

$140k - $160k/yr

No H1B Sponsorship

Remote in USA

Remote

Remote within the 50 United States, with occasional travel for team meetings or professional collaboration events.

Category
Sales & Account Management (1)
Required Skills
Sales
Data Science
Forecasting
CRM

Get referred to Synapticure

See people who can refer or advise you

Requirements
  • Direct pharmaceutical or life sciences experience, either selling services to pharmaceutical or biotechnology companies or working within a pharmaceutical or biotechnology organization in sales, medical affairs, health economics and outcomes research/real-world evidence, external innovation, or a similar function.
  • At least 8 years of professional experience, including at least 5 years in a commercial, business development, or partnership-facing role.
  • A demonstrated track record of closing complex, consultative, multi-stakeholder deals with pharmaceutical or biotechnology buyers.
  • Working fluency in the clinical research and/or real-world evidence landscape, including study designs, sponsor decision-making, budgets and contracting cycles, and the roles of contract research organizations, sites, and data partners.
  • Ability to translate ambiguous customer needs into concrete, scopeable service offerings.
  • Willingness to travel for conferences and partner meetings.
Responsibilities
  • Carry and deliver against an annual bookings and revenue target for Clinical Research and Real-World Evidence services sold to pharmaceutical and biotechnology partners.
  • Build and maintain a qualified pipeline through prospecting, outbound targeting of sponsor teams, conference-based sourcing, and expansion within existing accounts.
  • Lead the full deal cycle, including discovery, solutioning, proposal and statement-of-work development, pricing, negotiation, and closing, while coordinating internal subject-matter experts as needed.
  • Develop account plans for priority sponsors, including stakeholder mapping across therapeutic areas and functions and multi-year expansion paths.
  • Partner with clinical operations, data, and finance teams to scope engagements accurately and price them to protect margin and deliverability.
  • Maintain customer relationship management hygiene, accurate forecasting, and clear pipeline reporting to the senior vice president and executive team.
  • Represent Synapticure at industry conferences, sponsor meetings, and partner forums.
  • Sell Synapticure’s laboratory and diagnostic services where appropriate, either standalone or as part of broader research engagements.
  • Build and manage relationships with research-granting and advocacy foundations as funders, co-sponsors, and collaborators on research programs and registries.
  • Identify and pursue grant-funded and foundation-sponsored research opportunities, coordinating internally on responses to requests for proposals, requests for applications, and grant submissions.
  • Develop partnership and channel relationships with contract research organizations, positioning Synapticure as a site network, patient-access partner, real-world evidence data partner, or decentralized-trial delivery partner.
  • Track the funding landscape across disease areas to identify where Synapticure’s capabilities align with emerging research priorities.
  • Serve as the voice of the market in the design and refinement of Synapticure’s research offerings by translating sponsor and foundation requirements into service definitions, deliverables, and commercial models.
  • Partner with clinical, data, and product leadership to develop new research products and packaged offerings, including scope definition, pricing models, and go-to-market positioning.
  • Build and maintain sales-enabling assets, including capability decks, service one-pagers, case studies, proposal templates, and pricing frameworks.
  • Provide structured competitive and market intelligence on how sponsors are buying clinical research and real-world evidence services and where Synapticure is differentiated.
  • Work closely with clinical, operations, data, legal, and finance teams to ensure sold work is deliverable, contracted appropriately, and successfully transitioned to delivery.
  • Contribute to the Life Sciences team’s overall commercial strategy, target account prioritization, and annual planning.
Desired Qualifications
  • Working knowledge of pharmaceutical science and clinical care concepts, including drug development phases and endpoints, mechanisms of action, biomarkers and diagnostics, and how neurological conditions are diagnosed, staged, and managed in practice.
  • Experience in neurology, neurodegenerative disease, or rare disease.
  • Experience selling or delivering decentralized or virtual clinical trial services, patient recruitment and retention services, registries, or real-world evidence and real-world data offerings.
  • Existing relationships with sponsor research and medical affairs teams, advocacy foundations, or contract research organizations.
  • Experience contributing to service design, pricing, or product strategy in a growth-stage healthcare or life sciences company.
  • Experience selling into a market where the buyer set spans commercial, medical, and research budgets.

Synapticure provides 24/7 telehealth for people with neurodegenerative diseases, delivering virtual neurology and behavioral health care to patients and caregivers from home. How it works: patients book and receive care from neurologists, behavioral health providers, and care coordinators via telehealth, with integrated behavioral health services and up-to-date science guidance to help understand options and access new treatments or clinical trials. Revenue comes from fees for telehealth sessions, paid by patients, insurers, or both. How it stands out: a specialized focus on ALS, Alzheimer’s, Huntington’s, and Parkinson’s, plus care coordination and behavioral health integration, backed by founders with personal ALS experience and doctors who are described as empathetic and knowledgeable. Goal: improve access to expert neurodegenerative care, support patients and caregivers, and connect them with treatments and clinical trials through a science-informed virtual platform.

Company Size

51-200

Company Stage

Series A

Total Funding

$31.1M

Headquarters

Chicago, Illinois

Founded

2019

Get referred to Synapticure

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 16, 2026 ataxia launch expands addressable rare-disease patients beyond ALS and Parkinson’s.
  • June 11, 2026 MyBrainGuide collaboration channels distressed families directly into Synapticure intake.
  • CMS posted 2025 GUIDE outcomes: 25% fewer admissions, 35.8% fewer inpatient admissions.

What critics are saying

  • Synapticure depends on CMS GUIDE reimbursement; 2027 rule changes can crush economics.
  • Isaac Health now competes through MyBrainGuide, stealing dementia intake and payer relationships.
  • Multi-state telehealth and neurologist hiring strain operations; one staffing failure breaks nationwide coverage.

What makes Synapticure unique

  • Synapticure offers nationwide virtual neurologists for ALS, Parkinson’s, dementia, and ataxia.
  • Its CMS GUIDE presence spans all 50 states with caregiver respite coverage.
  • Biogen-backed ataxia launch adds genetic counseling, trial education, and longitudinal movement-disorder care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Remote Work Options

Home Office Stipend

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

0%

2 year growth

4%
Bionews, Inc.
Jul 21st, 2026
New virtual neurological care program launches for ataxia patients.

New virtual neurological care program launches for ataxia patients. Synapticure offers specialized evaluations, genetic counseling, and more The virtual care company Synapticure has launched a new program to offer remote neurological care for people with Friedreich's ataxia and other types of ataxia. According to a press release from Synapticure, the new program can in some cases serve as a patient's primary neurologist, or it can partner with existing care teams. Among other services, the program offers specialized evaluations, genetic counseling, comprehensive longitudinal care, and education about clinical trial opportunities, the company said. The new program will be led by Elizabeth Ferluga, MD, director of movement disorders at Synapticure. "Patients with ataxias are a community that has been underserved by the traditional healthcare system for far too long," Ferluga said. "The Synapticure model is transformative for this population - we can meet patients where they are, perform a thorough evaluation, help them understand their diagnosis and what it means for them and their families, provide information about potential clinical trials, and be a consistent, knowledgeable partner in their care over time. I am incredibly excited to bring this level of support to the ataxia community." Recommended Reading Synapticure aims to improve access to specialized treatment. Ataxia is a type of movement disorder characterized by a lack of balance and coordination. Friedreich's ataxia is one specific form of ataxia that is caused by mutations in the FXN gene. There are also many other forms of ataxia. Collectively, these conditions affect tens of thousands of people in the U.S. alone. People with ataxia typically rely on expert neurologists in order to receive optimal care. But actually finding neurologists with expertise in ataxia can be a major struggle, especially for people who don't live close to academic specialty centers. By offering a virtual option, Synapticure aims to make this type of specialized treatment easier to access. "For people living with ataxias and their families, accessing expert neurological care is often a years-long struggle," said Sandra Abrevaya, CEO and co-founder of Synapticure. "Synapticure was built to change that dynamic - to expand access to specialized neurological expertise directly to patients where they live, and to make personalized, proactive care the standard rather than the exception. We are proud to now open our doors to the ataxia community." The new ataxia program was launched in partnership with Biogen, the company that markets Skyclarys (omaveloxolone), which is currently the only approved treatment for Friedreich's ataxia in the U.S. Biogen is not directly involved in developing or administering the program, nor is the pharma company given a say in how patients receive care. "Highly specialized ataxia care and expertise can be difficult to find locally, posing a significant challenge for individuals and families," said Kristen Fortino, head of the U.S. rare disease franchise at Biogen. "Our commitment to people living with rare neurological diseases, including the broader ataxia community, extends beyond treatment. We are dedicated to providing meaningful support every step of the care journey including supporting greater awareness of available care resources." On a scale of 0 to 10, where 0 means "Not at all" and 10 means "Completely", to what extent do you generally trust the news or information you receive from Friedreich's Ataxia News? Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

PR Newswire
Jul 16th, 2026
Synapticure launches virtual ataxia care program with Biogen to expand neurology access nationwide

Synapticure has launched a virtual ataxia care programme, expanding access to specialised neurology care for adults across the United States living with ataxias — neurological conditions characterised by progressive loss of coordination, balance, and motor function. The virtual-first care model connects patients to expert neurologists, genetic counselling, and comprehensive longitudinal care delivered through Synapticure's independent healthcare providers. The programme will be led by Dr Elizabeth Ferluga, Director of Movement Disorders at Synapticure. Synapticure partnered with Biogen to support disease education and awareness efforts. Biogen is not involved in developing or administering the healthcare services. The programme offers virtual medical evaluations, at-home genetic testing, medication reviews, clinical trial education, and coordination with physical, occupational, and speech therapists. Ataxias affect tens of thousands of people in the United States. Synapticure's medical group is in-network with Medicare and various commercial insurance plans.

Modern Healthcare
Nov 21st, 2024
Top digital health funding: Morgan Health backs autism startup

In April 2023, Cortica received $75 million in a Series D funding round led by Optum Ventures.

FinSMEs
Nov 20th, 2024
Synapticure Raises $25M Series A

Synapticure, a Chicago, IL-based virtual care company dedicated to improving access and outcomes for patients and caregivers living with Alzheimer's and related dementias, Parkinson's, and other neurodegenerative diseases, raised $25M in Series A funding

Endpoints News
Nov 15th, 2024
SynaptiCure Raises $25M for Virtual Care

SynaptiCure has raised $25 million for its virtual approach to neurodegenerative disease care.